Trump’s bold drug pricing push delivers real savings on GLP-1 weight loss drugs and fertility treatments, slashing costs by half and putting relief in reach for struggling American families long burdened by Big Pharma greed.
Story Highlights
- GLP-1 medications like Ozempic and Wegovy now cost about $245 per month through Medicare, roughly half the previous price.
- Fertility drugs slashed dramatically: Cetrotide from $316 to $22.50, Gonal-F to $168 per pen, saving over $2,000 per IVF cycle.
- The TrumpRx.gov platform, launched in February 2026, lists 54 discounted drugs for direct access, bypassing insurance barriers.
- Agreements with Eli Lilly, Novo Nordisk, and EMD Serono expand Medicare coverage while enforcing most-favored-nation pricing.
Medicare Director Announces Major Price Cuts
Medicare Director Chris Klomp revealed that GLP-1 drug costs dropped roughly in half, with patients paying $245 per month for injectables like Ozempic, Mounjaro, Wegovy, and Zepbound through Medicare.
This follows agreements with Eli Lilly and Novo Nordisk in November 2025. The reductions address high out-of-pocket expenses that blocked one-quarter of Americans from filling prescriptions.
Families finally see relief from skyrocketing healthcare costs under President Trump’s second term.
Fertility Treatments Become Affordable for Families
The Trump administration secured an 84% discount on IVF therapies from EMD Serono, effective October 16, 2025. Gonal-F now costs as low as $168 per pen, Cetrotide $22.50, down from $316, and Ovidrel $84, down from $251.
Patients save more than $2,000 per cycle on average, easing the $3,000 to $7,000 out-of-pocket burden previously uncovered by insurance.
This supports family values by making parenthood accessible without government handouts or endless red tape.
TrumpRx.gov, launched in February 2026, offers GLP-1 vials at $350 monthly—a 30% discount—and oral formulations at $150 for the starting dose if FDA-approved.
Zepbound prices fell from $1,086 to $346. The platform lists 54 drugs, helping uninsured Americans compare and access savings directly.
Americans paying less as Trump drug pricing push slashes GLP-1, fertility medicine costs, official says https://t.co/9Zt7wC06qp
— FOX Business (@FoxBusiness) April 7, 2026
TrumpRx Platform Empowers Patients Against Big Pharma
TrumpRx aggregates manufacturer discounts and coupons, serving as a one-stop shop for cash-paying patients excluded from insurance coverage. It includes semaglutide products, tirzepatide, fertility injectables, and insulin.
Medicare covers Wegovy and Zepbound for obesity with comorbidities at $245, with $50 copays—far below Biden-era proposals. This limited-government approach forces fair pricing without bloating federal spending.
Pharma giants accepted most-favored-nation pricing, matching international rates, in exchange for expanded coverage.
State Medicaid programs gain access, potentially influencing 13 states already covering GLP-1s for obesity. Common-sense negotiations deliver results where leftist overregulation failed.
Director Klomp called it “delivering on affordability for every American family,” removing barriers to health.
The American Society for Reproductive Medicine noted that lower costs help fertility patients, though broader access needs work. These wins counter years of fiscal mismanagement and globalist policies that inflated costs.
Sources:
Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s
TrumpRx Discounts Only One Drug While 22 Million Americans See Costs Rise
American Society for Reproductive Medicine Responds to TrumpRx Announcement
Trump Wrong on Drug Pricing in State of the Union
TrumpRx Drugs Website Discount
